Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cardiomyocyte Maturation Associated lncRNA (CARMA) is a conserved long non-coding RNA located adjacent to MIR-1-1HG, the host gene for key cardiogenic microRNAs MIR1-1 and MIR-133a2. CARMA is transcribed antisense to these microRNAs and negatively regulates their expression. Knockdown of CARMA leads to increased expression of these microRNAs and further coordinate downregulation of their protein-coding targets, including RBPJ, a central effector in the NOTCH signaling pathway critical for cardiac development. CARMA thus forms part of a regulatory network involving lncRNAs, myomirs, and NOTCH pathway components, orchestrating the balance of differentiation and maturation in human pluripotent stem cell-derived cardiomyocytes[1]. Its function is critical for the specification of cardiac lineage and inhibition of neuroectodermal specification, but there is no evidence it acts as a classical therapeutic target such as a receptor, enzyme, or transporter[1][2].
not applicable (no known drugs or therapeutics target CARMA directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiomyocyte Maturation Associated long non-coding RNA (CARMA).